Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Comparable clinical outcomes after autologous matrix-induced chondrogenesis versus implantation of single patient-specific metal implants in focal femoral chondral lesions of the middle-aged patient” has been accepted for a podium presentation at the German Congress of Orthopaedics and Traumatology, DKOU 2022, which will take place in Berlin, Germany, on October 25-28, 2022. The presentation will be held by Priv.-Doz. Dr. med. Clemens Kösters, Maria-Josef-Hospital Greven, Germany.

“We have come to a stage where our Episealer®  Knee implant is not only used for patients who are too old for biological treatment alternatives, but also as a treatment for patients where biological treatment alternatives used to be the preferred option. We know from previous studies that our results are predictable, and we look forward to seeing the final results from this ongoing comparative study where our technology is compared with one of the most accepted biological treatment alternatives”, says Pål Ryfors, CEO Episurf Medical.